Acadia Pharmaceuticals (NASDAQ:ACAD) traded at a new 52-week high today of $38.48. Approximately 950,000 shares have changed hands today, as compared to an average 30-day volume of 1.4 million shares.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.
Potential upside of 8.2% exists for Acadia Pharmaceuticals, based on a current level of $37.75 and analysts' average consensus price target of $40.86. The stock should find initial support at its 50-day moving average (MA) of $32.89 and further support at its 200-day MA of $26.54.
Over the past year, Acadia Pharmaceuticals has traded in a range of $15.64 to $38.48 and is now at $37.75, 141% above that low. Over the past week, the 200-day moving average (MA) has gone up 1.4% while the 50-day MA has advanced 1.2%.